<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351282</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-SBRT</org_study_id>
    <nct_id>NCT04351282</nct_id>
  </id_info>
  <brief_title>SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma</brief_title>
  <official_title>SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary metastatic NPC patients received chemotherapy± immunotherapy, radiation for primary&#xD;
      tumors and SBRT for metastatic lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The eligible patients will receive 4-6 cycles chemotherapy±immunotherapy and radical&#xD;
      radiotherapy for nasopharyngeal tumors. Then, SBRT for oligometastatic lesions will be&#xD;
      assigned to eligible patients. The efficacy and side-effect will be evaluated and analyzed.&#xD;
      The relation of liquid biopsy data with treatment outcome（such as EBV DNA, CTCs, CTC&#xD;
      subtype，PD-L1 and so on）will be valued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>From date of diagnosis until the date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress free survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Previous Metastatic Progression Free Survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>From date of diagnosis until the date of first documented previous metastatic progression or date of death from any cause, whichever came first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Metastatic Free Survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>From date of diagnosis until the date of first documented new metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Number of Participants with acute or late toxicities</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Metastasis</condition>
  <condition>Stereotactic Body Radiation Therapy</condition>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-6 cycles of chemotherapy±immunotherapy and radical radiotherapy for nasopharyngeal tumors were given. SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.</description>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically conformed initial metastatic non-keratinizing nasopharyngeal carcinoma&#xD;
             (according to the 8th edition of AJCC/UICC stage system) and no PD was observed in&#xD;
             eligible patients after comprehensive treatment&#xD;
             (chemotherapy±immunotherapy+radiotherapy to primary tumor). Then, the metastic lesions&#xD;
             were PR/SD, and met the following requirement: the metastatic lesions ≤5 and&#xD;
             metastatic organs ≤2, no more than 3 metastastic lesions for a single organ (diameter&#xD;
             ≤ 5cm)&#xD;
&#xD;
          -  age 18-70 years old&#xD;
&#xD;
          -  Karnofsky scores ≥70&#xD;
&#xD;
          -  Estimated life ≥ 6 months&#xD;
&#xD;
          -  Adequate organ function including the following: Absolute neutrophil count (ANC) &gt;=&#xD;
             2.0 * 109/l; Platelets count &gt;= 100 * 109/l ;Hemoglobin &gt;= 90 g/dl; Creatinine&#xD;
             clearance &gt;= 60 ml/min; For patients without liver metastasis, AST and ALT &lt;= 1.5&#xD;
             times institutional upper limit of normal (ULN), Total bilirubin &lt;= 1.5 times&#xD;
             institutional ULN; For patients with liver metastasis, AST and ALT &lt;= 3 times&#xD;
             institutional upper limit of normal (ULN), Total bilirubin &lt;= 3 times institutional&#xD;
             ULN, with normal coagulation function, child-pugh grade A or B, normal liver tissue&#xD;
             volume &gt;700 mL&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who achieve complete remission after comprehensive treatment&#xD;
&#xD;
          -  Pathology confirmed as second primary tumor&#xD;
&#xD;
          -  Received radiotherapy at the corresponding site before, and overlapped with the site&#xD;
             of this radiotherapy&#xD;
&#xD;
          -  Femoral bone metastasis&#xD;
&#xD;
          -  With serious medical complications and contraindications of radiotherapy&#xD;
&#xD;
          -  With uncontrollable malignant pleural effusion&#xD;
&#xD;
          -  Positive pregnancy test for women of childbearing age or lactating women&#xD;
&#xD;
          -  Uncontrolled or active infections, such as immunodeficiency or HIV infection&#xD;
&#xD;
          -  Active mental disorder or other mental disorder that affects the patient's ability to&#xD;
             sign informed consent and understanding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiayun He, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

